The management of drug-drug interactions (DDIs) is a critical issue resulting from the overwhelming amount of information available on them. Natural Language Processing (NLP) techniques can provide an interesting way to reduce the time spent by healthcare professionals on reviewing biomedical literature. However, NLP techniques rely mostly on the availability of the annotated corpora. While there are several annotated corpora with biological entities and their relationships, there is a lack of corpora annotated with pharmacological substances and DDIs. Moreover, other works in this field have focused in pharmacokinetic (PK) DDIs only, but not in pharmacodynamic (PD) DDIs. To address this problem, we have created a manually annotated corpus consisting of 792 texts selected from the DrugBank database and other 233 Medline abstracts. This fined-grained corpus has been annotated with a total of 18,502 pharmacological substances and 5028 DDIs, including both PK as well as PD interactions. The quality and consistency of the annotation process has been ensured through the creation of annotation guidelines and has been evaluated by the measurement of the inter-annotator agreement between two annotators. The agreement was almost perfect (Kappa up to 0.96 and generally over 0.80), except for the DDIs in the MedLine database (0.55-0.72). The DDI corpus has been used in the SemEval 2013 DDIExtraction challenge as a gold standard for the evaluation of information extraction techniques applied to the recognition of pharmacological substances and the detection of DDIs from biomedical texts. DDIExtraction 2013 has attracted wide attention with a total of 14 teams from 7 different countries. For the task of recognition and classification of pharmacological names, the best system achieved an F1 of 71.5%, while, for the detection and classification of DDIs, the best result was F1 of 65.1%. These results show that the corpus has enough quality to be used for training and testing NLP techniques applied to the field of Pharmacovigilance. The DDI corpus and the annotation guidelines are free for use for academic research and are available at http://labda.inf.uc3m.es/ddicorpus.

The DDIExtraction Shared Task 2013 is the second edition of the DDIExtraction Shared Task series, a community-wide effort to promote the implementation and comparative assessment of natural language processing (NLP) techniques in the field of the pharmacovigilance domain, in particular, to address the extraction of drug-drug interactions (DDI) from biomedical texts. This edition has been the first attempt to compare the performance of Information Extraction (IE) techniques specific for each of the basic steps of the DDI extraction pipeline. To attain this aim, two main tasks were proposed: the recognition and classification of pharmacological substances and the detection and classification of drug-drug interactions. DDIExtraction 2013 was held from January to June 2013 and attracted wide attention with a total of 14 teams (6 of the teams participated in the drug name recognition task, while 8 participated in the DDI extraction task) from 7 different countries. For the task of the recognition and classification of pharmacological names, the best system achieved an F1 of 71.5%, while, for the detection and classification of DDIs, the best result was an F1 of 65.1%. The results show advances in the state of the art and demonstrate that significant challenges remain to be resolved. This paper focuses on the second task (extraction of DDIs) and examines its main challenges, which have yet to be resolved.

The early detection of drug-drug interactions (DDIs) is limited by the diffuse spread of DDI information in heterogeneous sources. Computational methods promise to play a key role in the identification and explanation of DDIs on a large scale. However, such methods rely on the availability of computable representations describing the relevant domain knowledge. Current modeling efforts have focused on partial and shallow representations of the DDI domain, failing to adequately support computational inference and discovery applications. In this paper, we describe a comprehensive ontology for DDI knowledge (DINTO), which is the first formal representation of different types of DDIs and their mechanisms and its application in the prediction of DDIs. This project has been developed using currently available semantic web technologies, standards, and tools, and we have demonstrated that the combination of drug-related facts in DINTO and Semantic Web Rule Language (SWRL) rules can be used to infer DDIs and their different mechanisms on a large scale. The ontology is available from https://code.google.com/p/dinto/.

If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

Exposure to minocycline for acne treatment during adolescence appears to have no effect on the incidence of SMI.